HCA surgery volumes dip in Q2, sending MedTech stocks lower
The news of HCA's decrease in surgical procedures for the second quarter is putting downward pressure on the MedTech sector as a whole.
Despite the negative news of a decrease in surgical cases, the recent candlestick pattern shows that after a sharp rise on July 28, the price has maintained a certain level, closing at $406.61 on August 3, indicating a stabilization of the downward trend. The current price is positioned above the resistance level ($375.0), suggesting that it is an appropriate time to assess the risks of a decline due to the news and the maintenance of the support level.
If the resistance level of $375.0 is broken and a rebound trend is confirmed, I will take profits with a target of $345.0. However, if the support level of $350.0 is breached and additional downward pressure occurs, I will cut losses at $370.0.
Based on the news flow and disclosure content, we maintained a conservative perspective while being cautious of the downside risk. However, the actual result recorded a return of 12.2%, significantly exceeding the predicted -3.2%. We overlooked the fact that the price's downward rigidity was stronger than the short-term downward pressure from the news. As a result, the prediction was off, but it confirmed the importance of not being solely focused on the news when reading market trends.
Even if the news has a strong negative nuance, if the closing price of the candlestick shows support, I will establish a judgment criterion that weighs the price's resilience more than the influence of the news itself. In particular, during periods when disclosures and news overlap, I will recognize the risks but will cultivate the sophistication to enter only after confirming that the price maintains itself within a specific range.